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Important Differences Between Short- and Long-Term Hemodynamic
Effects of Amiodarone in Patients With Chronic Ischemic Heart
Disease at Rest and During Ischemia-Induced Left
Ventricular Dysfunction
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Basel, Switzerland
To assessand compare the hemodynamic profileof short-
and long-term amiodarone administration in the same
set of patients and to investigate hemodynamic mecha-
nisms responsible for the antianginal effect of this drug,
10patients with documented coronary artery diseaseand
stable angina pectoris were studied. Simultaneous right
heart catheterization and equilibrium radionuclide an-
giocardiography were performed at rest and during ex-
ercise before therapy (control), after a 5 minute intra-
venous infusion of 7.5 mg/kg of amiodarone and after
21.0 ± 4.3 days ofperoraltherapy (10days 800 mg/day,
7 days 400 mg/day and then 200 mg/day). After acute
drug administration, ejection fraction, stroke index and
systolic blood pressure decreased, whereas heart rate,
left and right ventricular filling pressures and systemic
vascular resistance increased. These effects were re-
versed after long-term therapy; all measured values re-
turned to control levels except for heart rate, which
Amiodarone has been shown to be an effective antiar-
rhythmic agent in many supraventricular and ventricular
rhythm disorders (1-10). Whereas this effectiveness is vir-
tually undisputed with long-term amiodarone therapy (4-9),
there remains some controversy over its acute antiar-
rhythmic action as reflected by a disparity between clinical
and electrophysiologic effects (6, 11-14). This phenomenon
has been explained partly by the pharmacokinetic properties
of amiodarone, which differ markedly from those of other
antiarrhythmic drugs (15-19) but may also have a hemo-
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decreased below the control value, and right atrial pres-
sure, which remained slightlyelevated. Amiodarone drug
levels decreased from 4.8 ± 1.8 after intravenous in-
fusion to 1.2 ± 0.6 mg/liter after long-term therapy.
After adjustment for hemodynamicchanges at rest, there
were still significant reductions in heart rate, mean ar-
terial pressure and rate-pressure product during exercise.
It is concluded that the marked negative inotropic
effect of amiodarone administered acutely in the dose
applied calls for cautious use of this drug when admin-
istered intravenously. In contrast, long-term oral amio-
darone therapy seems hemodynamically safe, even in
patients with moderately depressed left ventricular func-
tion. Amiodarone also exerts a mild but significant anti-
ischemic effect, mainly through afterload reduction and
improvement in myocardial oxygen consumption.
(J Am Coil CardioI198S;S:120S-11)
dynamic basis or parallel. The hemodynamic action of amio-
darone has been studied (20-22) after acute administration
of the drug demonstrating negative inotropic and afterload-
reducing effects. In a recent study (23), the acute cardio-
depression seemed to disappear over a 24 hour observation
period of continuous amiodarone infusion. There is, how-
ever, little information on the long-term hemodynamic ef-
fects of this drug, and an intraindividual comparison be-
tween short- and long-term hemodynamic effects is lacking.
Moreover, although amiodarone was introduced for the
treatment of angina pectoris (24-26), there are almost no
data on hemodynamic mechanisms responsible for its an-
tianginal property.
The aim of the present investigation, therefore, was two-
fold: I) to assess and compare the hemodynamic profile of
short-term intravenous and long-term peroral amiodarone
administration at rest in the same set of patients, and 2) to
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study hemodynamic changesduringexercise in patientswith
chronic ischemicheart disease presentingwith stable angina
pectoris.
Figure 1. Study protocol showing the prestudy period (with dis-
continuation of antianginal therapy, clinical examination, exercise
electrocardiogram, thallium-201 scintigraphy, coronary angiog-
raphy and contrast ventriculography), as well as the three study
periods, namely, control, acute and chronic, with corresponding
dosages of amiodarone (AMIOD). CONC = concentration;
I.V. = intravenously.
Methods
Patients. Ten malepatients aged 54.1 ± 5.1 years (range
42 to 60) referred for evaluation of stable angina pectoris
(New York Heart Association functional classes II and III
despite medical therapy) were studied after informed con-
sent had been obtained (study protocol approved by this
institution's Ethics Committee on June 18, 1982). Included
were only patients in whom all antianginal drugs could be
withdrawnat least 48 hours (nitrates: 24 hours) before study
and who had neither a left ventricular ejection fraction of
less than 0.35, mitral incompetence, lung disease or thyroid
dysfunction. Three patients had a documented myocardial
infarction more than 3 months before this investigation.
Three'patients had one vessel disease and 7 had three vessel
disease, as documented in all 10 patients by coronary an-
giography. In addition, exercise-induced ischemiawasdem-
onstratedby distinct reversibleperfusiondefectsduring thal-
lium-Ztll scintigraphy (all 10 patients) and significant ST
segment depression (5 patients) at a symptom-limited max-
imal work load of 108.0 ± 29.4 watts.
Study protocol (Fig. 1). All patients had simultaneous
hemodynamic measurements and equilibrium radionuclide
angiocardiography at rest and during exercise before med-
ication (control period), immediately after 7.5 mg/kg of
amiodarone infused intravenously over 5 minutes (short-
term study) and after an average of 21.0 ± 4.3 days of oral
amiodarone treatment (long-term study; one patient refused
the second right heart catheterization, but had all other mea-
surements performed). For oral treatment, patients initially
received 800 mg/day of amiodaroneover 10days, followed
by 400 mg/day over 7 days and 200 mg/day thereafter up
to the long-term study. Amiodaronedrug levels were mea-
sured immediately after the short- and long-term hemody-
namic measurements (drug level determinations by high
pressure liquid chromatography performedat the Clin-Midy
Research .Center, Montpellier, France). Intravenous thyro-
tropin-releasin~ hormone tests to assess variablesof thyroid
functiort (free thyroxin index, free triiodothyronine index,
d-thyrotropin) were performed before any amiodarone
administration and during long-term amiodarone therapy.
Hemodynamic measurements. For standard hemody-
namic measurements and determination of cardiac output
accordingto the Fick method,a flow-guided ballooncatheter
was placed in the pulmonary artery. Oxygen consumption
for calculationof cardiacoutput wasdeterminedby a Hellige
oximeter. Because all patients had normal arterial oxygen
saturationat left heartcatheterization, this measurement was
assumed to remain unchanged for all further calculations
(27). Pressures were recorded using Hewlett-Packard 1280
transducers with midchest as reference. All variables were
analyzed by a dedicated Hewlett-Packard catheter computer
system. Peripheral blood pressure was measured using a
standard mercury sphygmomanometer; mean pressure was
approximated as diastolic pressure plus one-third of the pulse
pressure.
Equilibrium radionuclide data were accumulated at rest
and continuously during exercise for calculation of left
ventricular ejection fraction as previously described (28).
Equilibrium radionuclide angiocardiography was performed
after in-vivo red cell labeling with 25 mCi of technetium-
99m. Imagingwasaccomplished in the modified leftanterior
oblique projection with a conventional scintillation camera
equipped with a high sensitivitycollimator. Global left ven-
tricular ejection fraction was computed from composite time-
activity curves from a 2 minute acquisition period at rest
and at peak exercise using a special computer algorithm
(MUGE, Medtronic MDS-A2 computer system). Ejection
fraction valuesdeterminedby this techniquehave previously
been shown to correlate well with those of biplane cine-
angiography and to be reproducible (28,29). End-diastolic
volume was calculated by dividing hemodynamic stroke
volume by radionuclide ejection fraction.
Exercise studies. All patients underwent supine bicycle
exercise on an electronically braked Elerna-Schonander er-
gometer (type EM 350). which maintained a constant work
load for each patient during the entire exercise period over
a pedal rangeof 45 to 70 rpm. The exercise level previously
determined to produce anginal pain was used for all tests
in each patient. The exercise electrocardiogram was not
analyzed since only one lead was recorded for arrhythmia
monitoring and to serve as a trigger signal for the gated
radionuclide studies. We have previouslyshown that a sim-
ilar protocol provided reproducible results (30,31).
Statistical analysis. All data are presentedas mean val-
ues ± I standard deviation. Comparison of each treatment
period with corresponding control measurements was per-
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formed using the two-tailed t test for paired samples. For
comparison of the three measurements at rest (control, short-
and long-term), an analysis of variance was applied.
Subgroups of patients with moderately depressed left ven-
tricular function at rest as defined by an ejection fraction of
less than 0.50 (three patients) or a cardiac index of less than
2.6 (five patients) were separately analyzed and compared
with values in the remaining patients with normal left ven-
tricular function. Finally, analysis of covariance was used
for comparison of the three exercise periods after adjustment
for changes at rest. A p value of less than 0.05 was con-
sidered statistically significant.
Results
Hemodynamic effectsof amiodarone at rest. Short-
term effects. (Table J, Fig. 2). After intravenous admin-
istration of amiodarone, ejection fraction, stroke index and
systolic blood pressure decreased, whereas heart rate, left
and right ventricular filling pressures and systemic vascular
resistance increased. This resulted in no significant changes
in cardiac index, and end-diastolic volume index also re-
mained virtually unchanged. Thus, a marked negative ino-
tropic effect was noted acutely.
Long-term effects. These short-term changes were re-
versed after 3 weeks of amiodarone treatment. All measured
values returned to control levels, except for heart rate which
had decreased below and right atrial pressure which was
still higher than values before treatment. The difference
between short- and long-term hemodynamic effects as com-
pared with control measurements is shown in Figure 3,
indicating that the acute cardiodepression caused by amio-
darone was almost completely reversed after chronic therapy.
A comparison of hemodynamic changes in subgroups of
patients with normal versus moderately abnormal left ven-
tricular function at rest revealed no statistically different
Table 1. Hemodynamic Results Before (control) and After Short- and Long-Term Amiodarone Therapy
Short-TermTherapy Long-Term Therapy
p Versus p Versus p Versus
Control Value Control Value Short-Tenn Control
HR (min-I)
Rest 72.2 ± 11.0 77.9 ± 10.2 <0.01 66.7 ± 12.8 <0.01 <0.05
Ex 115.7 ± 18.8 113.5 ± 14.3 NS 104.9 ± 13.5 <0.01 <0.01
SBP (mm Hg)
Rest 133.0 ± 14.4 127.5 ± 16.4 <0.05 137.5 ± 15.1 NS NS
Ex 182.5 ± 23.4 170.5 ± 24.4 <0.01 181.5 ± 24.4 <0.05 NS
DBP (rnrn Hg)
Rest 86.5 ± 7.5 89.5 ± 10.1 NS 88.0 ± 12.9 NS NS
Ex 103.5 ± 5.8 95.5 ± 9.6 <0.05 94.5 ± 10.9 NS <0.05
CI (Iiters/min-rn/)
Rest 2.9 ± 0.6 2.5 ± 0.9 NS 3.0 ± 0.4 NS NS
Ex 4.6 ± 0.9 4.2 ± 1.4 NS 4.9 ± 0.6 NS NS
SI (ml/rrr')
Rest 40.9 ± 11.2 33.2 ± 13.3 <0.01 47.3 ± 8.4 <0.05 NS
Ex 40.4 ± 10.1 38.0 ± 16.7 NS 47.7 ± 7.7 NS <0.05
EF(%)
Rest 54.1 ± 11.2 44.3 ± 10.3 <0.001 56.4 ± 13.4 <0.001 NS
Ex 44.2 ± 10.7 42.7 ± 11.6 NS 48.3 ± 12.9 <0.01 NS
SVR (dynes-s-cmP)
Rest 1,461 ± 343 1,704 ± 519 <0.05 1,373 ± 281 NS NS
Ex 1,137 ± 210 1,194 ± 333 NS 974 ± 203 NS <0.05
PeW (mm Hg)
Rest 10.3 ± 2.8 13.9 ± 2.9 <0.001 12.1 ± 2.4 <0.05 NS
Ex 24.2 ± 6.8 27.7 ± 5.5 <0.05 26.7 ± 5.8 NS NS
RAP (mm Hg)
Rest 5.3 ± 1.6 7.5 ± 1.7 <0.001 7.0 ± 1.7 NS <0.01
Ex 8.6 ± 2.4 9.6 ± 2.5 NS 11.0 ± 2.6 NS <0.01
EDVI (ml/nr')
Rest 80.6 ± 33.8 81.8 ± 48.4 NS 88.3 ± 31.2 NS NS
Ex 99.9 ± 48.5 101.0 ± 68.1 NS 109.0 ± 46.7 NS NS
CI = cardiac index; DBP = diastolic blood pressure; EDVI = end-diastolic volume index; EF = ejection fraction; Ex = exercise; HR = heart
rate; p = significance; PeW = pulmonary capillary wedge pressure; RAP = right atrial pressure; SBP = systolic blood pressure; SI = stroke index;
SVR = systemic vascular resistance.
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behavior; that is, acute cardiodepressant effects and their
reversion after long-term amiodarone therapy were similar
in both subgroups. At the same time, amiodarone drug levels
decreased from 4.8 ± 1.8 after intravenous infusion to
1.2 ± 0.6 mg/liter after long-term therapy (p < 0.001),
whereas desethylamiodarone, the main metabolite, in-
creased from a nondetectable level after infusion to 0.64 ±
O. 17 mg/liter after long-term therapy in 9 of the 10 patients.
Hemodynamic effects of amiodarone during exer-
cise. The directional changes induced by amiodarone on
hemodynamic variables during exercise were similar to those
observed at rest, but in general they were smaller (Table
I). After adjustment for these changes at rest, however,
there was still a significant reduction in heart rate and mean
systemic blood pressure (Fig. 4). Therefore, the rate-pres-
sure product as an index of myocardial oxygen consumption
improved significantly. It is important to note that after
intravenous amiodarone infusion ischemia-induced left ven-
tricular dysfunction, as indicated by decreased ejection frac-
tion and increased left ventricular filling pressure, showed
no further deterioration. After long-term therapy, exercise
stroke index increased and vascular resistance decreased
relative to control values.
Clinical and side effects. Amiodarone was well toler-
ated in all patients, although 6 of the 10 experienced a
transient flush phenomenon of varying intensity during ini-
tial drug infusion. No rhythm disturbances were recorded.
None of these patients with medically refractory angina
became symptom-free after acute or chronic amiodarone
therapy. Five patients reported an increased need for nitrates
during the study period as compared with their previous
drug regimen (mostly beta-receptor blocking drugs or cal-
cium-channel antagonists, or both), although anginal pain
was less severe subjectively in 8 of the 10 patients during
the short-term exercise versus control study. Thyroid func-
tion remained normal in seven patients, whereas free thy-
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roxin index values increased to the borderline hyperthyroid
range in three patients with normal intravenous triiodothy-
ronine indexes (no hyperthyroidism).
Figure 4. Effect of amiodarone (acute/chronic) on exercise-in-
duced changes of hemodynamic variables vs. control after ad-
justment for drug-induced changesat rest (analysis of covariance).
EX = exercise;MP = meanarterialpressure;other abbreviations
as in Figure 2.
in systemic vascular resistance and left ventricular filling
pressure. In contrast, Sicart (21) and Cote (22) and their
coworkers observed an increase in heart rate and cardiac
index and a decrease in systemic vascular resistance. Al-
though these differing hemodynamic patterns during the
initial minutes after bolus injection have been explained in
part by the effects of the solvent (Tween 80), Sicart et al.
(21) reported that the action of the solvent characterized by
a decrease in aortic pressure and vascular resistance and an
increase in heart rate lasted only up to 4 minutes after in-
travenous injection. Bellotti et al. (23), infusing amiodarone
not dissolved in Tween 80, had results similar to ours when
infusing amiodarone over 5 minutes. The negative inotropic
effect was even more pronounced in our study, most likely
because the higher dose (7.5 mg/kg) used probably masked
any solvent effects. Such high doses are used clinically today
(10), even though experimentally the reduction in contrac-
tility is hardly perceptible at doses up to 5 rng/kg but be-
comes significant at 10 mg/kg (21). The marked acute car-
diodepressant effects most likely were responsible for the
observed acute (reflex) increases in systemic vascular re-
sistance and heart rate.
It has recently been shown (32) that the negative inotropic
effect of short-term amiodarone administration seems to be
even more pronounced in patients with a severely depressed
left ventricular ejection fraction « 0.30). Even after slow
drug infusions of 5 mg/kg over 20 minutes, overt heart
failure and profound hypotension occurred in two of nine
patients (32), and similar deleterious effects were observed
by Benaim et al. (33). Therefore, such patients were not
included in the present investigation. Analysis of subgroups
of patients with moderately depressed left ventricular func-
tion in our study revealed similar cardiodepressant effects
when compared with patients with normal ventricular func-
tion. Although well established standard hemodynamic
methods have been used, minor methodologic limitations
of this study may result from indirect measurement of sys-
temic arterial pressure by inflatable cuff.
Chronic hemodynamic effects of amiodarone. After
24 hours of amiodarone infusion in patients with Chagas'
disease, vascular resistance decreased relative to short-term
measurements, and cardiac index returned to normal due to
peripheral vasodilatory effects (23). These results are very
similar to those observed after 3 weeks of oral amiodarone
in our patients with ischemic heart disease. In addition, there
was a decrease in heart rate at this time in both studies,
probably as a result of sinus node depression (11,34,35).
All other hemodynamic variables returned to control levels
except for persistently elevated right ventricular filling pres-
sures, suggesting a persistent minimal negative inotropic
effect. This improvement in cardiac function was paralleled
by a significant decrease in amiodarone drug levels, which
remained well in the range accepted for chronic antiar-
rhythmic effectiveness (18,19,36), even though drug levels
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Discussion
In this study, the hemodynamic profiles of amiodarone
infused intravenously and administered orally over 3 weeks
differed substantially in the same set of patients with chronic
ischemic heart disease. Significant cardiodepression was the
predominant mechanism in the short -term study, whereas
negative chronotropic effects and afterload reduction pre-
vailed with long-term treatment. These latter two mecha-
nisms could also be shown to play a major role in the
antianginal mode of action of amiodarone.
Acute hemodynamic effects of amiodarone. In pre-
vious short-term hemodynamic studies using a dose of 5
mg/kg, Ourback (20) and Bellotti (23) and their coworkers
noted a similar decrease in cardiac index with an increase
- 10
Figure 3. Hemodynamic effects of acute and chronicamiodarone
therapyat restcomparedwithcontrolvalues. Percentchangesfrom
control values (~%) are shown on the ordinate. CI = cardiac
index; EDVI = end-diastolic volume index; EF = ejection frac-
tion; HR = heart rate; I.V. = intravenous; PCW = pulmonary
capillary wedgepressure; P.O. = oral; SI = stroke index; SP =
systolicbloodpressure;SVR = systemicvascularresistance. Sig-
nificance according to analysis of variance.
A'f,
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of amiodarone and its metabolites may not truly reflect active
tissue concentrations of this drug.
Effects of amiodarone on exercise-induced isch-
emia. During exercise-induced ischemia, amiodarone ex-
erted its antianginal effects by significant reductions in heart
rate and systolic blood pressure; that is, myocardial oxygen
consumption improved as demonstrated by a slight increase
in stroke index. In addition, previous studies have reported
increases in coronary blood flow (22) and spasmolytic ef-
fects (37). Still, the improvement in ischemia-induced left
ventricular dysfunction after amiodarone was not very im-
pressive (either hemodynamically or clinically) and seemed
smaller than that observed in similar studies with nitro-
glycerin, beta-adrenergic blocking drugs or nifedipine (30,3I).
Side effects of amiodarone. Amiodarone was well tol-
erated except for an initial transient flush of variable inten-
sity in a majority of patients. Side effects on thyroid function
were not significant during the short observation period of
this study. More severe side effects have been described
(38-42) after longer amiodarone administration and with
higher doses.
Implications. In view of the marked negative inotropic
effect observed after a 5 minute intravenous infusion of 7.5
mg/kg of amiodarone, this study calls for cautious use of
intravenous amiodarone, especially in patients with de-
pressed left ventricular function. There is some evidence
that this cardiodepressant action may be less important with
smaller doses and at slower rates of infusion. In contrast,
long-term use of amiodarone seems to be hemodynamically
safe even in patients with moderately depressed left ven-
tricular function. Besides its antiarrhythmic properties,
amiodarone exerts a mild but significant antiischemic effect
mainly by afterioad reduction and improvement in myo-
cardial oxygen consumption and may, therefore, be espe-
cially suitable for patients with chronic ischemic heart disease.
We thank the Clin-Midy Research Center in Montpellier, France for de-
termining amiodarone drug levels and performing statistical analyses. We
appreciate the excellent technical assistance of our cardiology and nuclear
medicine staffs and we are indebted to Cathy Faes for her secretarial
assistance.
References
I. Singh BN, Vaughan Williams EM. The effect of arniodarone, a new
antianginal drug, on cardiac muscle. Br J Pharmacol 1970;89:657-67.
2. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of
amiodarone as an antiarrhythmic agent. Am J Cardiol 1976;38:934--44.
3. Wellens H11, Brugada P, Abdollah AH. Effect of amiodarone in
paroxysmal supraventricular tachycardia with or without the Wolff-
Parkinson-White syndrome. Am Heart J 1983;106:876-9.
4. Rosenbaum M, Chiale PA, Ryba D, Elizari MV. Control of tachyar-
rhythmias associated with Wolff-Parkinson-White syndrome by amio-
darone hydrochloride. Am J Cardiol 1974;34:215-23.
5. Graboys TB. Podrid PJ. Lown B. The efficacy of amiodarone for
refractory supraventricular tachyarrhythmias. Am Heart J 1983;
106:916-21.
6. Heger 11, Prystowsky EN, Jackman WM, et al. Clinical efficacy and
electrophysiology during long-term therapy for recurrent ventricular
tachycardia or ventricular fibrillation. N Engl J Med 1981;305:539-45.
7. Leak D, Eydt IN. Control of refractory cardiac arrhythmias with
amiodarone. Arch Intern Med 1979;139:425-8.
8. Podrid PJ, Lown B. Amiodarone therapy in symptomatic, sustained
refractory atrial and ventricular tachyarrhythmias. Am Heart J
1981;101:374-9.
9. Kaski JC, Girotti LA, Messuti H, Rutitzky B, Rosenbaum MB. Long-
term management of sustained recurrent symptomatic ventricular
tachycardia with amiodarone. Circulation 1981 ;64:273-9.
10. Faniel R, Schoenfeld PH. Efficacy of i.v.amiodarone in converting
rapid atrial fibrillation and flutter to sinus rhythm in intensive care
patients. Eur Heart J 1983;4:180-5.
II. Wellens H11, Brugada P, Roy D, Abdollah H, Dassen WR. A com-
parison of the electrophysiological effects of intravenous and oral
amiodarone in the same patient. Circulation 1984;69:120-4.
12. Hamer AW, Finerman WB, Peter T, Mandel WJ. Disparity between
the clinical and electrophysiologic effects of amiodarone in the treat-
ment of recurrent ventricular tachyarrhythmias. Am Heart J
1981;102:992-1000.
13. Waxman HL, Groh WC, Marchlinski FE, et al. Amiodarone for con-
trol of sustained ventricular tachyarrhythmias: clinical efficacy and
electrophysiologic effects in 51 patients. Am J CardioI1982;50:1066--74.
14. Nademanee K, Hendrikson JA, Kaman R, Singh BH. Antiarrhythmic
efficacy and electrophysiologic actions of amiodarone in patients with
life-threatening ventricular arrhythmias: potent suppression of spon-
taneously occurring tachyarrhythmias versus inconsistent abolition of
induced ventricular tachycardia. Am Heart J 1982;103:950-9.
15. Moret PR, Boufas D, Fournet Pc. Proprietes pharmacologiques d'un
nouvel anti-angoreux: I' Amiodarone. Schweiz Med Wochenschr
1969;90:1090-7.
16. Charlier R, Deltour G, Baudine A, Chaillet F. Pharmacology of amio-
darone, an anti-anginal drug with a new biological profile. Arzneim
Forsch 1968;18:1408-17.
17. Andreasen F, Agerbaek H, Bjerregaard P, Gotzsche H. Pharmaco-
kinetics of amiodarone after intravenous and oral administration. Eur
J Clin Pharmacol 1981;19:293-9.
18. Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone phar-
macokinetics. Am Heart J 1983;106:840-6.
19. Kannan R, Nademanee K, Hendrickson JA, Rostmi HJ, Singh BN.
Amiodarone kinetics after oral dose. Clin Pharmacol Ther 1982;
31:438-44.
20. Ourback P, Rocher R, Aziza JP, et al. Effets hemodynamiques de
I'injection intraveineuse de chlorhydrate d'amiodarone chez Ie sujet
normal et Ie coronarien. Arch Mal Coeur 1976;69:293-302.
21. Sicart M, Besse P, Choussat A, Bricaud H. Action hernodynamique
de l'amiodarone intraveineuse chez l'homme, Arch Mal Coeur
1977;70:219-302.
22. Cote P, Bourassa MG, Delaye J, Janin A, Froment R, David P. Effects
of amiodarone on cardiac and coronary hemodynamics and on myo-
cardial metabolism in patients with coronary artery disease. Circulation
1979;59:1165-72.
23. Bellotti B, Silva LA, Filho AE, et al. Hemodynamic effects of intra-
venous administration of amiodarone in congestive heart failure from
chronic Chagas' disease. Am J Cardiol 1983;52:1046-9.
24. Vastesaeger M, Gillot P, Rasson G. Etude clinique d'une nouvelle
medication anti-angoreuse. Acta Cardiol 1967;22:483-500.
25. Leutenegger A, Liithy E. Eine neue Substanz in der Therapie der
Angina pectoris: Amiodarone. Schweiz Med Wochenschr 1968;
98:2020-5.
26. Zelvelder WG. Investigation of the therapeutic activity of amiodarone
JACC Vol. 5. No.5
May 1985:1205-11
PFISTERER ET AI..
HEMODYNAMIC EFFECTS OF AMIODARONE
1211
(Cordarone)in the treatmentof angina pectoris. Eur J Clin Pharmacol
1971 ;3:158-62.
27. Astrand PO. Textbook of Work Physiology. New York: McGraw-
Hill. 1970:160.
28. Pfisterer M, Ricci DR, Schuler G, et al. Validity of left ventricular
ejectioh fractions measured at rest and peak exercise by equilibrium
radionuclide angiography using short acquisition times. J Nucl Med
1979;20:484-90.
29. Pfisterer M. Battler A, Swanson SM. Slutsky R. Froelicher V, Ash-
burn WL. Reproducibility of ejection fractiondeterminations by equi-
librium radionuclide angiography in response to supine bicycle ex-
ercise. J Nucl Med 1979;20:491-5.
30. Pfisterer M, Muller-Brand J. Burkart F. Combined acebuto-
lol/nifedipine therapy in patientswith chroniccoronaryartery disease:
additional improvement of ischemia-induced left ventricular dysfunc-
tion. Am J Cardiol 1982;49: 1259-66.
31. PfistererM, Glaus L. BurkartF. Comparative effects of nitroglycerin,
nifedipine and metoprolol on regional left ventricular function in pa-
tientswithone-vesselcoronarydisease. Circulation 1983:67:291-301.
32. SchwartzA, ShenE, MoradyF, GillespieK, ScheinmanM. Chatterjee
K. Hemodynamic effects of intravenous amiodarone in patients with
depressed left ventricular function and recurrent ventriculartachycar-
dia. Am Heart J 1983;106:848-55.
33. Benaim R. Bernier A, Ameur A. Acute depressive effect of amio-
darone on cardiac function (abstr). Eur Heart J I984;5(suppl 1):283.
34. CoutteR, FontaineG, FrankR, Dragodanne C. Phan-Thuc H, Facquet
J. Etude electrocardiologique des effets de I'amiodarone sur la con-
duction intracardiaque chez l'homme. Ann Cardiol Angeiol 1976;
6:543-8.
35. TouboulP. AtallahG, GressardA, KirkorianG. Effectsofamiodarone
on sinus node in man. Br Heart J 1979;42:573-8.
36. Siddoway LA. McAllisterCB. Wilkinson GR. Roden OM, Woosley
RL. Ainiodarone dosing: a proposal based upon its pharmacokinetics.
Am Heart J 1983;106:951-6.
37. Rutitzsky B, Girotti AL, Rosenbaum MB. Efficacy of chronic amio-
darone therapy in patients with variant angina pectoris and inhibition
of ergonovine coronary constriction. Am Heart J 1982;103:38-43.
38. Kaplan U. Cappaert WE. Amiodarone keratopathy-correlation to
dosage and duration. Arch Ophthalm 1982;100:601-2.
39. Burger A, DinichettC, Nicod P. Jenny N. LeMarchand BP, Valloton
MB. Effect of amiodarone on serum triiodothyronine, reverse triio-
dothyronine. thyroxin and thyrotropin. A drug influencing peripheral
metabolism of thyroid hormones. J C1in Invest 1976;58:255-9.
40. Kaeser HE. Amiodarone-Neuropathie. Schweiz Med Wochenschr
1974;104:606-8.
41. Rikita L. Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary
toxicity. Am Heart J 1983;106:906-14.
42. Fogoros RN. Anderson KP, Winkle RA, Swerdlow CD. Mason JW.
Amiodarone: clinicalefficacyand toxicityin 96 patientswith recurrent
drug refractory arrhythmias. Circulation 1983;68:88-94.
